We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Gene Therapy Combined with Stem Cell Technology Cures Inherited Anemia

By LabMedica International staff writers
Posted on 10 Jun 2009
In a proof-of-concept study carried out on cells growing in tissue culture, researchers have shown that gene therapy combined with induced pluripotent stem (iPS) cell technology can cure a rare form of inherited chronic anemia.

Fanconi anemia (FA) is an inherited disorder responsible for a series of hematologic abnormalities that impair the body's ability to fight infection, deliver oxygen, and clot blood. The syndrome is caused by mutations in one of 13 Fanconi anemia (FA) genes, and is characterized by bone marrow failure, leukemia, and other cancers. Treatment includes bone marrow transplants to correct the hematological problems. However, patients remain at high risk of developing cancer and other serious health conditions.

Investigators at the Center of Regenerative Medicine (Barcelona, Spain) started by growing somatic cells from Fanconi anemia patients in tissue culture. To correct the hematologic aspect of the disease a normal copy of the mutated gene was introduced into the cells using a viral vector. Then the investigators transformed the repaired cells into induced pluripotent stem (iPS) cells using a combination of transcription factors, OCT4, SOX2, KLF4, and cMYC. The resulting FA-iPS cells were indistinguishable from human embryonic stem cells and iPS cells generated from healthy donors.

The corrected Fanconi-anemia-specific iPS cells gave rise to hematopoietic progenitors of the myeloid and erythroid lineages that were phenotypically normal, that is, disease-free.

"It has been ten years since human stem cells were first cultured in a Petri dish,” said senior author Dr. Juan-Carlos Izpisúa Belmonte, director of the Center of Regenerative Medicine. "The hope in the field has always been that we will be able to correct a disease genetically and then make iPS cells that differentiate into the type of tissue where the disease is manifested and bring it to clinic. We have not cured a human being, but we have cured a cell,” said Dr. Belmonte. "In theory we could transplant it into a human and cure the disease.”

Related Links:

Center of Regenerative Medicine



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
New
Rapid Sepsis Test
SeptiCyte RAPID

Latest BioResearch News

Study Links Midlife Vitamin D to Lower Tau in Alzheimer's
10 Jun 2009  |   BioResearch

International Consensus Standardizes Tumor Microbiota Detection and Reporting
10 Jun 2009  |   BioResearch

Common Metablolic Enzyme Could Predict Response to Cancer Immunotherapy
10 Jun 2009  |   BioResearch